The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.
and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.
The approvals were based on a study that showed patients aged between 10 years and 17 years recorded lower average blood sugar compared with placebo when treated with empagliflozin - the active ingredient in the two drugs.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stock Market News: S&P 500 slides, Eli Lilly’s buys Dice, missing sub latestStocks wobble following the long holiday weekend, Eli Lilly buys Dice Therapeutics for $2.4 billion, Alibaba names new CEO, housing starts and permits jump and the search continues for the missing submarine touring the Titanic wreck site. FOX Business is providing real-time updates on the markets, commodities and all the most active stocks on the move.
Read more »
Dice Therapeutics rallies as it agrees to be bought by LillyDice Therapeutics Inc. stock is up by 40% in premarket trades Tuesday after it agreed to be purchased by Eli Lilly & Co. for $48 a share in a deal that...
Read more »
Update: U-KISS Reveals New Concept Photos Of Alexander, Eli, And AJ For “PLAY LIST” ComebackUpdate: U-KISS Reveals New Concept Photos Of Alexander, Eli, And AJ For “PLAY LIST” Comeback
Read more »
FDA OKs Drug for Cholestatic Pruritus in Alagille SyndromeOdevixibat is indicated for treatment of cholestatic pruritus associated with Alagille syndrome in patients as young as 12 months. It marks the second indication for the drug.
Read more »
FDA OKs Low-Dose Colchicine for Broad CV IndicationThe drug represents the first specific anti-inflammatory drug for the reduction of cardiovascular events for patients with established atherosclerotic disease or with multiple risk factors.
Read more »